| 1 |
34505146 | Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression. | 2022 Feb 21 |
5 |
| 2 |
35042121 | Amiloride is a suitable fluorescent substrate for the study of the drug transporter human multidrug and toxin extrusion 1 (MATE1). | 2022 Feb 12 |
1 |
| 3 |
35163393 | Transport Turnover Rates for Human OCT2 and MATE1 Expressed in Chinese Hamster Ovary Cells. | 2022 Jan 27 |
2 |
| 4 |
35183887 | Tamsulosin alters the pharmacokinetics of metformin via inhibition of renal multidrug and toxin extrusion protein 1 and organic cation transporter 2 in rats. | 2022 Apr 1 |
1 |
| 5 |
33262224 | Impact of Direction of Transport on the Evaluation of Inhibition Potencies of Multidrug and Toxin Extrusion Protein 1 Inhibitors. | 2021 Feb |
2 |
| 6 |
34097256 | Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects. | 2021 Jul |
1 |
| 7 |
34151116 | Why Should Metformin Not Be Given in Advanced Kidney Disease? Potential Leads from Computer Simulations. | 2021 Jun 15 |
6 |
| 8 |
34265779 | Transporters, TBC1D4, and ARID5B Variants to Explain Glycated Hemoglobin Variability in Patients with Type 2 Diabetes. | 2021 |
1 |
| 9 |
34388523 | The L125F MATE1 variant enriched in populations of Amerindian origin is associated with increased plasma levels of metformin and lactate. | 2021 Oct |
5 |
| 10 |
32444490 | Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1. | 2020 Jun 9 |
3 |
| 11 |
32472157 | A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers. | 2020 Aug |
3 |
| 12 |
32551505 | A Multiplexed HILIC-MS/HRMS Assay for the Assessment of Transporter Inhibition Biomarkers in Phase I Clinical Trials: Isobutyryl-Carnitine as an Organic Cation Transporter (OCT1) Biomarker. | 2020 Jul 21 |
1 |
| 13 |
31012983 | Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study. | 2019 Oct |
3 |
| 14 |
29480578 | Houttuynia cordata extract increased systemic exposure and liver concentrations of metformin through OCTs and MATEs in rats. | 2018 Jun |
1 |
| 15 |
29862627 | Mapping of biguanide transporters in human fat cells and their impact on lipolysis. | 2018 Oct |
1 |
| 16 |
30191328 | Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. | 2018 Sep 6 |
1 |
| 17 |
30294927 | Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1. | 2018 Nov |
1 |
| 18 |
30433870 | Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients. | 2018 Dec 19 |
1 |
| 19 |
27871888 | Multidrug and toxin extrusion proteins mediate cellular transport of cadmium. | 2017 Jan 1 |
1 |
| 20 |
28069720 | Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin. | 2017 Mar |
1 |
| 21 |
28321905 | Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes. | 2017 Jul |
2 |
| 22 |
28546950 | Genetic polymorphisms of multidrug and toxin extrusion proteins (MATE1 and MATE2) in South Indian population. | 2017 |
2 |
| 23 |
28947922 | Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver. | 2017 |
2 |
| 24 |
28971610 | Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine. | 2017 Oct |
3 |
| 25 |
26597253 | The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. | 2016 Jun |
3 |
| 26 |
26784938 | The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment. | 2016 Apr |
9 |
| 27 |
26977146 | The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients. | 2016 |
3 |
| 28 |
27019345 | Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions. | 2016 Jun 10 |
1 |
| 29 |
27180666 | [Pharmacogenetics of oral antidiabetic treatment]. | 2016 Mar |
1 |
| 30 |
27324407 | Limited sampling strategy for determining metformin area under the plasma concentration-time curve. | 2016 Oct |
1 |
| 31 |
27555891 | Pharmacogenetic studies update in type 2 diabetes mellitus. | 2016 Aug 10 |
1 |
| 32 |
25753371 | Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). | 2015 Jun |
2 |
| 33 |
26004431 | SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. | 2015 Jul |
8 |
| 34 |
26426900 | Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. | 2015 |
1 |
| 35 |
26552145 | [Establishment of MDCK cell models expressing human MATE1 or co-expressing with human OCT1 or OCT2]. | 2015 Jul |
1 |
| 36 |
25125398 | Development of an LC-MS/MS method for high throughput quantification of metformin uptake in transporter inhibition assays. | 2014 Sep 15 |
1 |
| 37 |
25394090 | The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. | 2014 |
2 |
| 38 |
22882994 | Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. | 2013 Feb |
3 |
| 39 |
23267855 | The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. | 2013 Feb |
5 |
| 40 |
23305245 | Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. | 2013 Nov |
1 |
| 41 |
23558289 | Identification and functional characterization of novel MATE1 genetic variations in Koreans. | 2013 May 3 |
3 |
| 42 |
23873119 | A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. | 2013 Oct |
2 |
| 43 |
23894862 | Pharmacogenetics and personalized treatment of type 2 diabetes. | 2013 |
1 |
| 44 |
24026623 | Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. | 2013 Dec |
1 |
| 45 |
24238901 | The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo. | 2013 Dec 15 |
1 |
| 46 |
24324494 | Pharmacogenetics of oral antidiabetic drugs. | 2013 |
1 |
| 47 |
22735389 | Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. | 2012 Sep |
2 |
| 48 |
20883471 | Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. | 2011 Jun |
2 |
| 49 |
21241070 | Clinical pharmacokinetics of metformin. | 2011 Feb |
1 |
| 50 |
21677353 | [Metformin - mechanisms of action and use for the treatment of type 2 diabetes mellitus]. | 2011 May 6 |
2 |